Compare · ATRC vs WST
ATRC vs WST
Side-by-side comparison of AtriCure Inc. (ATRC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 9.9x ATRC ($2.48B).
- ATRC has been more active in the news (5 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $2.48B
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 5
- 1
- Recent ratings
- 14
- 18
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ATRC
- AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.
- Director Prange Karen sold $138,283 worth of shares (3,564 units at $38.80), decreasing direct ownership by 14% to 22,809 units (SEC Form 4)
- Director Yuen Maggie sold $134,470 worth of shares (3,500 units at $38.42), decreasing direct ownership by 20% to 14,015 units (SEC Form 4)
- President, CEO, & Director Carrel Michael H gifted 4,700 shares, decreasing direct ownership by 0.60% to 774,434 units (SEC Form 4)
- Chief Scientific Officer Doraiswamy Vinayak sold $233,280 worth of shares (6,000 units at $38.88), decreasing direct ownership by 6% to 86,511 units (SEC Form 4)
- Director Wehrwein Sven exercised 25,000 shares at a strike of $19.95 and sold $946,000 worth of shares (25,000 units at $37.84) (SEC Form 4)
- Chief Mktg & Strategy Officer Noznesky Justin J sold $239,862 worth of shares (6,182 units at $38.80), decreasing direct ownership by 6% to 100,219 units (SEC Form 4)
- SEC Form 144 filed by AtriCure Inc.
- SEC Form S-8 filed by AtriCure Inc.
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target